Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bayer acquires full Vitrakvi rights from Eli Lilly’s Loxo

German drugmaker Bayer acquired all rights the company does not already own in Vitrakvi, a drug against a variety of cancers driven by a rare genetic mutation, from Eli Lilly’s Loxo Oncology.

Read More »

Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China

Samsung Bioepis Co. Ltd. announced the company’s expansion in mainland China through a licensing agreement with C-Bridge Capital. The transaction covers multiple biosimilar candidates from Samsung Bioepis, including third-wave biosimilar candidates SB11 and SB12 – which reference Lucentis (ranibizumab) and Soliris (eculizumab) – as well as the biosimilar candidate SB3 that references Herceptin (trastuzumab).

Read More »

Argenx and Halozyme Ink Multiple Target Deal

Argenx and Halozyme Therapeutics signed a global collaboration and license deal that allows Argenx to use Halozyme’s Enhanze drug delivery technology to develop multiple products.

Read More »

Janssen and MeiraGTx Sign $440 Million Deal to Develop Gene Therapies for Eye Diseases

Janssen Pharmaceutical, a Johnson & Johnson company, inked a worldwide collaboration and license deal with MeiraGTx to develop, manufacture and commercialize a portfolio of drugs for inherited retinal diseases.

Read More »

Weeks After $74 Billion Acquisition, Celgene Strikes Two Cancer Deals

Ahead of being absorbed by Bristol-Myers Squibb, Celgene forged a strategic collaboration with two companies to develop immuno-oncology treatments and cell therapies.

Read More »

Walgreens and Microsoft partner to develop digital healthcare services

Drugstore chain Walgreens Boots Alliance Inc. and Microsoft Corp said they have entered a seven-year agreement to research and develop new methods of delivering healthcare services through digital devices.

Read More »

Lilly eyes more cancer deals, but wary of CAR-T, gene therapy

Eli Lilly and Co. remains in the hunt for cancer drugs even after announcing an $8 billion purchase of Loxo Oncology, but the company plans to remain on the sidelines when it comes to two of the hottest areas of drug development.

Read More »

Healthcare deals raise pulse of U.S. lending in 2019

Bankers are diagnosing another robust year for U.S. healthcare lending as the first two big loans of 2019 include the largest-ever tie-up in the pharmaceutical sector, and more are expected.

Read More »

GlaxoSmithKline to look for early-stage assets: CEO

GlaxoSmithKline Plc will actively look to buy early-stage assets and partner with companies, the drugmaker’s chief executive officer said.

Read More »

Sanofi to pay Regeneron $462 million in revised immuno-oncology deal

Sanofi will pay Regeneron about $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body’s own immune system fight cancer.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom